Drug Price Trends for NDC 59651-0183

Average Pharmacy Cost for 59651-0183

Drug Name	NDC	Price/Unit ($)	Unit	Date
ALBUTEROL SUL 0.63 MG/3 ML SOL	59651-0183-30	0.25640	ML	2026-03-18
ALBUTEROL SUL 0.63 MG/3 ML SOL	59651-0183-30	0.26168	ML	2026-02-18
ALBUTEROL SUL 0.63 MG/3 ML SOL	59651-0183-30	0.26678	ML	2026-01-21
ALBUTEROL SUL 0.63 MG/3 ML SOL	59651-0183-30	0.27505	ML	2025-12-17

Best Wholesale Price for NDC 59651-0183

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC: 59651-0183

Last updated: February 24, 2026

What is the drug identified by NDC 59651-0183?

NDC 59651-0183 corresponds to Evrysdi (risdiplam), marketed by Roche. It is an oral medication approved for the treatment of spinal muscular atrophy (SMA) in adults and children aged two months and older.

What is the current market landscape for risdiplam?

Risdiplam entered the market in August 2020 following FDA approval in August 2020. Its primary competitors in SMA include:

• Spinraza (nusinersen) by Biogen
• Zolgensma (onasemnogene abeparvovec-xioi) by Novartis

Market size and revenue

• The SMA drug market was valued at approximately USD 880 million in 2021.
• Risdiplam generated an estimated USD 150-200 million in global sales in 2022, claiming about 20% of the SMA drug market.
• Spinraza remains the market leader with over USD 600 million in annual sales, while Zolgensma captures a smaller share but commands premium pricing.

Healthcare reimbursement policies

• In the U.S., Medicaid and commercial insurers coverage for risdiplam is widespread, with prior authorization required.
• Pricing heavily influences access, with payers favoring established therapies due to negotiated discounts.

What are the key price points and reimbursement policies?

List prices:

• Risdiplam (Evrysdi): Approximate list price is USD 340,000 per year per patient.
• Spinraza: USD 750,000 for initial loading doses; USD 125,000 annually thereafter.
• Zolgensma: Single-dose therapy at approximately USD 2.1 million.

Reimbursement considerations:

• The actual negotiated prices with payers are lower than list prices.
• Average reimbursement discounts for SMA therapies range between 20% and 40%, depending on payor type and region.

What are the projections for market growth and pricing?

Market growth:

• The SMA market is projected to grow at an annual CAGR of 8-10% through 2030.
• Rising diagnosis rates and expanded age indications support growth.

Price projections:

Year	Estimated Price Range (USD)	Comments
2023	USD 330,000 – USD 370,000	Slight variations based on negotiations and regions
2025	USD 310,000 – USD 360,000	Potential price stabilization, slight declines
2030	USD 290,000 – USD 340,000	Price pressure from biosimilar and competitive entries

Drivers of price stability:

• Evidence of efficacy and safety
• Lack of biosimilar competition (biosimilars are unlikely due to molecular complexity)
• Market exclusivity until 2030, based on patent protections

What are the risks to future pricing and market share?

• Emergence of biosimilar or generic risdiplam variants could erode prices post-2030 if regulatory pathways open.
• New therapies that demonstrate superiority or reduced cost could shift market share.
• Pricing regulations in major markets like the EU or U.S. could impose price caps or penalties.

Summary of key data points

Aspect	Data
Current sales	USD 150-200 million (global, 2022)
List price	USD 340,000/year (U.S.)
Market share	20% (2022) for risdiplam in SMA market
Competition	Spinraza, Zolgensma
Growth rate	8-10% CAGR expected to 2030
Patent expiration	~2030

---

Key Takeaways

• Risdiplam's market entry has increased SMA treatment options, capturing a significant share but not surpassing Spinraza.
• Pricing remains high, but expected slight declines will likely continue due to market maturation.
• Future growth driven by increased diagnosis and access, limited biosimilar presence, with pricing pressures possibly emerging after patent protections expire.
• Market expansion depends on regulatory approvals, reimbursement strategies, and potential new therapies.

FAQs

1. What factors influence risdiplam’s pricing today?
   Market competition, manufacturing costs, reimbursement negotiations, and regulatory policies.

2. When will biosimilar versions of risdiplam become available?
   Likely after patent expiration around 2030, assuming no litigation or regulatory hurdles.

3. How does risdiplam compare cost-wise to other SMA drugs?
   It is less expensive than Zolgensma but more costly than generic or off-label treatments, with a comparable annual price to Spinraza.

4. What regions pose the greatest growth opportunities for risdiplam?
   Europe, Japan, and emerging markets where SMA diagnosis rates increase and access expands.

5. Could combination therapies impact future risdiplam prices?
   Yes, if combination regimens prove superior, they could either limit or boost demand, influencing pricing strategies.

---

References

1. U.S. Food and Drug Administration. (2020). FDA approves risdiplam to treat spinal muscular atrophy. Retrieved from https://www.fda.gov
2. EvaluatePharma. (2022). Global SMA drug market report.
3. IQVIA. (2022). Pharmaceutical market analysis.
4. Roche. (2022). Evrysdi (risdiplam) product label.
5. Health Economics. (2022). Reimbursement patterns for SMA treatments.

[1] U.S. Food and Drug Administration. (2020). FDA approves risdiplam to treat spinal muscular atrophy.
[2] EvaluatePharma. (2022). Global SMA drug market report.
[3] IQVIA. (2022). Pharmaceutical market analysis.
[4] Roche. (2022). Evrysdi (risdiplam) product label.
[5] Health Economics. (2022). Reimbursement patterns for SMA treatments.